1. Corporate Presentation INDOCO REMEDIES LTD

2. About Us  Indian Company with an International presence  Turnover 09-10; Rs. 402.36 Crores,  Turnover 1 HY – FY11 : 246.23 Crores  Among the fastest growing Indian Companies  Ranked 24th in ORG IMS Rx Audit on MAT basis (ORG October 2010)  Complete solution provider  CRAMS – R&D, Regulatory & Mfg  USFDA & MCC SA approved sterile Ophthalmic facility  UK MHRA, German Darmstad, ANVISA Brazil, MCC SA approved tablets, creams & capsules facility  R&D and Regulatory capabilities  Employs 3000 people  100 R&D scientists  1700 field staff

3. Our Infrastructure  Corporate Office  Manufacturing Facilities  5 Formulations facilities  2 API facilities  R&D Centre  Depots & Branches  34 Branches  Domestic Marketing Network  7 divisions  PAN INDIA presence

4. Our Business  Indian Business  Branded Generic Formulations  APIs  International Business  Regulated Markets  Generics  CRAMS  APIs  Emerging Markets  Branded Generic Formulations  APIs

5. Indian Business  INDOCO – GP, CP, Gynaec, Life Style  SPADE – GP, CP, Paediatrician  WARREN – Dental, ENT  EXCEL – Opthal  SPERA – GP, Gynaec, Paediatrician  XTEND – GPs in Extra Urban Towns  ETERNA – CPs, Orthos, Gastro

6. International Presence

7. Formulations Infrastructure SITEDOSAGE FORMSTATUS GOA ITABLETSUK MHRA, GERMAN BRAZIL ANVISA, MCC SA, TGA CREAMS & OINTMENTSUK MHRA GOA IISTERILE EYEDROPSUS FDA, MCC SA GOA IIITABLETSUK MHRA, GERMAN BRAZIL ANVISA, MCC SA, TGA PILOT TABLET CAPSULES WALUJTABLETSROW BADDITABLETS & LIQUID ORALSSCHEDULE M UK MHRA, TGA, Slovenian Authorities CREAMS & OINTMENTS TOOTHPASTES

8. API Infrastructure  KILO PLANT  Reaction Systems: 16 to 500 L  Total Reactor Volume: 1 cubic meters  Temperatures range: -55 to + 150 celsius  MULTI-TON PLANT  Reactor Capacity: 500 to 4000 L  Total Reactor Volume: 55 cubic meters  NEW OPHTHALMIC FACILITY  Reactor Capacity: 500 to 2000 L  Total reactor Volume: 15 cubic meters  INTERMEDIATES FACILITY  Reactor Capacity: 500 to 4000 L  Total Reactor Volume: 50 cubic meters

9. R & D  The state-of-art, stand alone, US $ 10 million R & D center for Formulations, API & Intermediates is located at Rabale- near New Mumbai  The R & D center in a area of 70,000 Sq.feet is designed to accommodate more than 200 scientists and technical personnel  This center is equipped with all required sophisticated hardware and software  The state of art cGMP standard KILO LAB is a part of this Research Center

10. R & D F&D Regulatory API Research

11. F & D NDDS GENERICS CONTRACT RESEARCH CONTRACT MFG DOMESTIC PIPELINE  Over 50 Scientists working estimated to go up to 75 next year.  Launched 12 new products during last year  Completed 20 and currently working on 19 euro dossiers, completed 3 and working on 9 ANDA projects. These are Indoco’s own IP.  Filed 9 ANDAs for various US partners. 3 Already Approved  926 Formulation Dossiers of 161 products submitted to 54 countries & 20 products are under preparation for 13 countries.  Executing contracts for Development work for International Companies. Multiple site transfer projects and Euro Dossiers completed to the satisfaction of the European Customers.

12. API ( R&D) CONTRACT RESEARCH CUSTOM SYNTHESIS GENERICS API R&D SYNTHETIC CHEMISTRY SCALE UPIPRANALYTICALKILO LAB

13. Regulatory 8 USDMF 1 DMF for Canada 4 EU DMF 5 COS REG AFFAIRS API US DMF JDMFCOS EU DMF

14. Regulatory Submitted 60 dossiers to various customers in Europe, New Zealand, Australia & SA 56 in Pipeline REG AFFAIRS ANDACTD DOSSIERS

15. CRAMS

16. Performance Highlights  Integrated player  R&D, Manufacturing & Marketing in both API & Formulations  Strong presence in India  Ranked 22nd in Rx Audit (IMS ORG-Sep 10)  Ranked 31st in Retail Audit (IMS ORG-Sep 10)  Focused on exports  International Sales estimated to grow more than 35%  Forging strong partnerships such as Watson & Aspen

17. Analysis ofProfit and Loss Account Analysis of Profit and Loss Account Rs. In Lacs PARTICULARS QUARTERLY HALF YEARLYYEARLY Quarter Ended Sept 10 Quarter Ended Sept 09 % Growth Half Year Ended 30.09.10 Half Year Ended 30.09.09 % Growth Year Ended 31.03.2010 INCOME SALES & OPERATIONS 13378963038.9 %246231955526.0 %40231 LESS : EXCISE (144)(87) (251)(178)(402) NET SALES 13234954338.7 %243721937725.8 %39829 ADD : OPERATING INCOME 31064 459293490 TOTAL INCOME 13544960740.9 %248311967026.2 %40319 EXPENDITURE MATERIALS 60554073 10921810317391 STAFF COST 18541446333027405646 OTHER EXPENSES 33332553 6178495010453 EBIDTA 2302153550.1 %4402387713.6 %6829 R&D EXPENSES 2182254104731022 INTEREST 5366118159291 DEPRECIATION 3352896565681210 MISC. EXP.WRITTEN OFF 12249 OPERATING PROFIT 1913117862.4 %3626314615.3 %5319 PAT 152692565.0%3008261315.1 %4209

18. Growth Drivers Present domestic marketing set up Focus on high value products such as anti infective, GI products, etc. Intensive Pan – India coverage of medical fraternity through various marketing divisions. Partnering with Watson and Aspen Strong R&D Set up New Plants at Goa and Waluj

19. Thank you very much